MAP2K7 and melanoma: MEK inhibition is a treatment already clinically approved and frequently used for the treatment of melanoma, and clinical trials investigating the efficacy of MEK inhibitors for non-small cell lung cancer, colon cancer and thyroid cancer are currently ongoing (e.g., NCT03085056, NCT03704688).